4-iodomethyl-2-(4-methoxyphenyl)-5-methyloxazole | 501363-01-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-iodomethyl-2-(4-methoxyphenyl)-5-methyloxazole
• 英文别名: 2-(4-methoxyphenyl)-4-iodomethyl-5-methyloxazole；4-(iodomethyl)-2-(4-methoxyphenyl)-5-methyl-1,3-oxazole
• CAS: 501363-01-5
• 化学式: C₁₂H₁₂INO₂
• 分子量: 329.137
• InChiKey: CUPROPFTDOKVRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(cis-3-hydroxycyclohexyloxymethyl)-6-methylbenzoate 、 4-iodomethyl-2-(4-methoxyphenyl)-5-methyloxazole 在 C27H31NO6 作用下， 以gave the product 71 of molecular weight 465.55 (C27H31NO6), MS(ESI)的产率得到2-{3-[2-(4-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid
  参考文献：
  名称：

  Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals

  摘要：

  本发明公开了二芳基环烷基衍生物及其生理上可接受的盐和生理上功能衍生物。这些化合物包括公式I中的基团所定义的那些基团及其生理上可接受的盐和制备它们的过程。这些化合物通常具有降脂和/或降三酰甘油的特性，例如，适用于治疗脂质代谢障碍，2型糖尿病和X综合症等疾病。

  公开号：

  US20050267177A1
• 作为产物：
  描述：

  碘化钠 、 4-(氯甲基)-2-(4-甲氧基苯基)-5-甲基噁唑 在 甲基叔丁基醚 、 disodium;dioxido-oxo-sulfanylidene-λ6-sulfane 、 magnesium sulfate 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 4-iodomethyl-2-(4-methoxyphenyl)-5-methyloxazole
  参考文献：
  名称：

  OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS

  摘要：

  本发明涉及氧化二氮杂环酮及其生理上可接受的盐和生理上功能衍生物，其显示过氧化物酶体增殖物激活受体（PPAR）δ激动剂活性，包括式I中的化合物，其中R1-R7取代基以及U、V、W、X、Y和z基团的定义如本文所述，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病；中枢神经系统和/或周围神经系统的神经退行性疾病和/或去髓鞘疾病以及涉及神经炎症过程和/或其他周围神经病的神经疾病。

  公开号：

  US20080255212A1

文献信息

• Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
  申请人：——

  公开号：US20030144332A1

  公开（公告）日：2003-07-31

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披萨店的员工们正在忙着准备今晚的外卖订单。
• Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209920A1

  公开（公告）日：2004-10-21

  Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

  芳基环烷基取代的烷基酸衍生物，其制备方法及其作为药物的用途。该发明涉及芳基环烷基取代的烷基酸衍生物及其生理可接受的盐和生理功能衍生物。所描述的化合物为式I，其中基团如所定义，以及其生理可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍、葡萄糖利用障碍以及胰岛素抵抗相关的疾病。
• Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Stapper Christian

  公开号：US20050101637A1

  公开（公告）日：2005-05-12

  Provided herein are novel compounds of formula I below: in which the radicals are as defined, their physiologically acceptable salts, processes for their preparation, as well as methods of treating and/or preventing disorders of disorders of fatty acid metabolism and glucose utilization disorders, and also of disorders in which insulin resistance is involved, in a patient.

  本文提供了以下公式I的新化合物： 其中基团的定义如下，它们的生理学上可接受的盐，其制备过程，以及治疗和/或预防患者体内脂肪酸代谢和葡萄糖利用障碍，以及胰岛素抵抗相关的障碍的方法。
• Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Stapper Christian

  公开号：US20050215596A1

  公开（公告）日：2005-09-29

  Provided herein are cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals

  本文提供了环烷基取代的氨基酸衍生物，其制备过程以及作为药物的用途。
• METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS
  申请人：KEIL Stefanie

  公开号：US20080262052A1

  公开（公告）日：2008-10-23

  The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or de-myelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.

  本发明涉及氧化二唑酮及其生理上可接受的盐和生理上功能衍生物，显示PPARδ激动剂活性。所描述的化合物为公式I中的基团，其定义如上，并且它们的生理上可接受的盐和制备过程。该化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗涉及的疾病；中央和周围神经系统的神经退行性疾病和/或去髓鞘疾病和/或涉及神经炎症过程和/或其他周围神经病变的神经疾病。